- Home
- MAIA vs TIL Comparison
MAIA vs TIL Comparison
Compare MAIA & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAIA
- TIL
- Stock Information
- Founded
- MAIA 2018
- TIL 2018
- Country
- MAIA United States
- TIL United States
- Employees
- MAIA N/A
- TIL N/A
- Industry
- MAIA Biotechnology: Pharmaceutical Preparations
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- MAIA Health Care
- TIL Health Care
- Exchange
- MAIA Nasdaq
- TIL Nasdaq
- Market Cap
- MAIA 56.3M
- TIL 177.1M
- IPO Year
- MAIA 2022
- TIL 2021
- Fundamental
- Price
- MAIA $1.69
- TIL $24.94
- Analyst Decision
- MAIA
- TIL Buy
- Analyst Count
- MAIA 0
- TIL 6
- Target Price
- MAIA N/A
- TIL $120.50
- AVG Volume (30 Days)
- MAIA 450.2K
- TIL 142.0K
- Earning Date
- MAIA 11-11-2025
- TIL 11-12-2025
- Dividend Yield
- MAIA N/A
- TIL N/A
- EPS Growth
- MAIA N/A
- TIL N/A
- EPS
- MAIA N/A
- TIL N/A
- Revenue
- MAIA N/A
- TIL N/A
- Revenue This Year
- MAIA N/A
- TIL N/A
- Revenue Next Year
- MAIA N/A
- TIL N/A
- P/E Ratio
- MAIA N/A
- TIL N/A
- Revenue Growth
- MAIA N/A
- TIL N/A
- 52 Week Low
- MAIA $1.40
- TIL $10.80
- 52 Week High
- MAIA $3.62
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- MAIA 58.17
- TIL 45.29
- Support Level
- MAIA $1.54
- TIL $22.67
- Resistance Level
- MAIA $1.78
- TIL $25.50
- Average True Range (ATR)
- MAIA 0.09
- TIL 2.44
- MACD
- MAIA 0.02
- TIL -0.49
- Stochastic Oscillator
- MAIA 72.19
- TIL 20.34
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.